Study results expected soon may show Takeda Pharmaceutical's drug Actos does not have the heart-attack risk claimed for GlaxoSmithKline's Avandia. One study indicates Actos protects against blood clots that cause heart attacks, and a pending review of past studies may confirm the finding, a Takeda official said.

Full Story:

Related Summaries